Medical Devices & Equipment - Patient Monitoring & Hospital Automation
Strategic Profile
In 2025, Masimo achieved a record level of incremental contract value from new customers and expanded hospital agreements with existing customers, positioning the company well for sustained performance in the year ahead. The company has outlined a long-term strategic vision to strengthen its position as a global leader in patient monitoring, expand its innovation pipeline, with updated 2028 financial targets including revenue growth of 7%-10% on a compound annual basis and operating margins approaching 30%.
Cyborg Score Rationale
Masimo demonstrates solid fundamentals with double-digit market cap (~$7B), consistent revenue growth (9% in 2025), strong institutional ownership, and a market leadership position in pulse oximetry. Analyst sentiment is mixed (buy/hold majority vs. sell ratings), and valuation appears elevated at ~4.3x P/S. The company faces near-term headwinds from tariffs and cyclical capital equipment demands but maintains strong long-term guidance.
Top Insights
Preliminary Q4 2025 revenue of ~$411M (+12% reported) and full-year 2025 revenue of ~$1,523M (+9%) demonstrate solid growth momentum despite tariff headwinds.
Masimo's earnings have surpassed Zacks Consensus Estimate in each of the trailing four quarters with an average surprise of 12.4%.
Management expects capital equipment revenues to remain less predictable and more cyclical than consumables in 2026, with growth driven by timing of large contracts rather than steady demand.
Hospital Automation and SafetyNet platforms are improving and automating care delivery both in the hospital and beyond, representing key diversification from traditional monitoring devices.
Named Competitors
Philips Monitoring Solutions — Integrated hospital patient monitoring and care systems
GE Healthcare Monitoring — Patient monitoring and medical imaging systems
Medtronic Patient Monitoring — Broad medical device portfolio including monitoring solutions
Nonin Pulse Oximetry — Pulse oximetry and noninvasive monitoring devices
Recent Developments
(February 2026) Announced preliminary 2025 financial results showing $1.523B revenue (+9% YoY) and expects full results February 26, 2026
(February 2026) Market cap at $6.99-7.39B with trading at moderate premium to fair value amid mixed analyst sentiment
(2025) Achieved record incremental contract value from new hospital customers and expanded agreements with existing customers
Open the full interactive Masimo Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.